BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
Business Insider14h
AstraZeneca put volume heavy and directionally bearish
Bearish flow noted in AstraZeneca (AZN) with 57,094 puts trading, or 10x expected. Most active are Nov-24 75 puts and Nov-24 70 puts, with total volume in those strikes near 33,200 contracts. The ...
It News Online17h
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion ...
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
George Soros Makes a Strategic Move with a 6.25% Stake in Smurfit WestRock PLC
Smurfit WestRock PLC (NYSE:SW), with a substantial acquisition of 6,896,971 shares, making up 6.25% of the portfolio and ...
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
AirBnB and 5 More High-Quality Stocks for a Market Rally
All 11 sectors are in the green for the year. The optimism comes as the economy is likely to continue to grow because the ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...